RMD Open

is an open access, peer-reviewed rheumatology journal that publishes original research on rheumatic and musculoskeletal disorders and connective tissue diseases

Impact Factor: 5.1
Citescore: 7.3
All metrics >>

RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.

It is an online only open access journal that aims to provide rapid publication of research through a continuous publication model. All submitted content is subject to peer review prior to publication. Published work is free to read.

Follow the journal on X for the latest updates.

Editorial team

Current Issue

Authors

RMD Open accepts submissions of a wide range of article types, including original research, analysis and practice articles, and commentaries.

The Author Information section provides specific article requirements to help you turn your work into an article suitable for RMD Open.

Information is also provided on editorial policies and open access.

Author information Submit a paper

Latest Articles

Rheumatoid arthritis:

Systematic screening for multimorbidities in patients with inflammatory rheumatic diseases enhanced preventive medication use and reduced hospitalisations: an exposed-non-exposed study

2 October 2024

Sjo[x0308]gren syndrome:

Development of a web-based ecological momentary assessment tool to measure day-to-day variability of the symptoms in patients with Sjögrens disease

2 October 2024

Rheumatoid arthritis:

Forefoot inflammation in recent-onset ACPA-positive and ACPA-negative RA: clinically similar, but different in underlying inflamed tissues

2 October 2024

Sjo[x0308]gren syndrome:

Conception in women with primary Sjögren's disease

2 October 2024

Video Abstract

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

30 January 2024

Conclusions: Bimekizumab demonstrated a safety profile consistent with previous reports; no new safety signals were identified. Sustained efficacy was observed from weeks 16 to 52.

Find out more